104 related articles for article (PubMed ID: 38810204)
1. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
Wechsler ME; Fan Y; Merkel PA
N Engl J Med; 2024 May; 390(20):1940. PubMed ID: 38810204
[No Abstract] [Full Text] [Related]
2. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?
Akdime F; Puéchal X; Roche N
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2942-2943. PubMed ID: 34246444
[No Abstract] [Full Text] [Related]
3. Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?".
Caminati M; Crisafulli E; Lunardi C; Micheletto C; Festi G; Maule M; Giollo A; Orsolini G; Senna G
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2943-2944. PubMed ID: 34246445
[No Abstract] [Full Text] [Related]
4. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab.
Chica-Guzmán MV; Morillo-Guerrero R; Carrón-Herrero A; González-de-Olano D; Almonacid-Sánchez C
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):228-230. PubMed ID: 32407950
[No Abstract] [Full Text] [Related]
6. Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis.
Lee Y; Hojjati M
J Clin Rheumatol; 2021 Dec; 27(8S):S401-S402. PubMed ID: 32453217
[No Abstract] [Full Text] [Related]
7. Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).
Bandla M; Howard M; McNally A; Armstrong D; Simpson I; Mar A
Australas J Dermatol; 2023 Aug; 64(3):404-407. PubMed ID: 37195732
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab in eosinophilic granulomatosis with polyangiitis.
Laorden D; Romero D; Domínguez-Ortega J
Med Clin (Barc); 2022 May; 158(9):441-442. PubMed ID: 34728088
[No Abstract] [Full Text] [Related]
9. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab and Eosinophilic Pleural Effusion in Patient With Eosinophilic Granulomatosis With Polyangiitis.
Lorenzo Martínez MDC; Clavería García O; Herrero Mendoza MD; Jareño Esteban JJ
Arch Bronconeumol; 2023 Jul; 59(7):439-440. PubMed ID: 37059683
[No Abstract] [Full Text] [Related]
11. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab to treat eosinophilic granulomatosis with polyangiitis.
Callejas Rubio JL; Moreno Higueras M; Ortego Centeno N
Med Clin (Barc); 2024 Feb; 162(3):140. PubMed ID: 37567822
[No Abstract] [Full Text] [Related]
13. Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.
Anai M; Yoshida C; Ozono K; Furukawa H; Ishimaru Y; Sakata S; Saruwatari K; Muramoto K; Tomita Y; Saeki S; Ichiyasu H; Sakagami T
Allergol Int; 2022 Apr; 71(2):259-261. PubMed ID: 35074267
[No Abstract] [Full Text] [Related]
14. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
15. Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study.
Bettiol A; Urban ML; Bello F; Fiori D; Mattioli I; Lopalco G; Iannone F; Egan A; Dagna L; Caminati M; Negrini S; Bargagli E; Folci M; Franceschini F; Padoan R; Flossmann O; Solans R; Schroeder J; André M; Moi L; Parronchi P; Roccatello D; Sciascia S; Jayne D; Prisco D; Vaglio A; Emmi G;
Ann Rheum Dis; 2022 Dec; 81(12):1769-1772. PubMed ID: 35850947
[No Abstract] [Full Text] [Related]
16. Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: Case series and literature review.
Kamide Y; Watai K; Nakamura Y; Iwata M; Fukutomi Y; Taniguchi M; Sekiya K
Allergol Int; 2024 Jan; 73(1):180-183. PubMed ID: 37852914
[No Abstract] [Full Text] [Related]
17. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab.
Hočevar A; Kopač P; Rotar Ž; Novljan MP; Škrgat S
J Allergy Clin Immunol Pract; 2020; 8(7):2448-2449. PubMed ID: 32304835
[No Abstract] [Full Text] [Related]
18. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.
Ozola L; Aleksejeva E; Stoldere D; Dāvidsone Z; Šantere R; Grantiņa I; Cīrule I; Krams A
Pediatr Pulmonol; 2023 Mar; 58(3):973-979. PubMed ID: 36404638
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
